EXACT Sciences Corp. (EXAS) DNA Technology Included in Colorectal Cancer Screening Guidelines
EXACT Sciences Corp. (NASDAQ: EXAS) today announced its stool-based DNA (sNDA) technology is included in updated guidelines concerning colorectal cancer screening from the American Cancer Society and the U.S. Multi-Society Task Force on Colorectal Cancer. In a collective statement, Dr. Sidney Winawer, attending gastroenterologist, and Paul Sherlock, chair in medicine at Memorial Sloan-Kettering Cancer Center, said new guidelines were set in place to urge more people to take the tests. "In addition to colonoscopy and other previously recommended tests, two new options have been included in the guidelines for colorectal cancer screening; stool DNA testing and CT colonography," they stated…